FDA approves Ryoncil for steroid-refractory acute graft-versus-host after allo-HSCT
The allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy Ryoncil (remestemcel-L-rknd) has been approved for ...
Mesoblast After Approval: Stock Is Buoyant Now, But Unpredictable Overall
Mesoblast's FDA approval for remestemcel marks a milestone for MSC therapies, but limited cash reserves pose risks for US ...
Why Appen, Brainchip, Liontown, and Mesoblast shares are falling today
Liontown Resources Ltd (ASX: LTR) and Mesoblast Ltd (ASX: MSB) are two of four ASX shares falling on Friday. Here's ...
Zacks.com on MSN14d
MESO Stock Up as FDA Approves Ryoncil for Graft Versus Host Disease
The FDA approves Mesoblast's Ryoncil (remestemcel-L) for treating pediatric patients with steroid-refractory acute graft ...
Cure Today15d
Ryoncil Receives FDA Approval for Children With GVHD
This marks the first mesenchymal stromal cell therapy approved by the FDA for children with acute graft versus host disease.
clinicaladvisor.com8d
Mesenchymal Stromal Cell Therapy Ryoncil Gets FDA Approval
The ORR was 70% in patients treated with remestemcel-L, with 30% having a complete response and 41% having a partial response. The Food and Drug Administration (FDA) has approved Ryoncil ...
Mesoblast awarded FDA approval for Ryoncil
Mesoblast (ASX:MSB) has received approval from the US Food and Drug Administration (FDA) for Ryoncil (remestemcel-L), making ...
5 ASX All Ords shares starting the new year at 52-week highs
S&P/ASX All Ords Index (ASX: XAO) shares closed higher on the first day of trading for 2025, with these stocks clocking new ...
Pharmaceutical Technology on MSN14d
FDA approves Mesoblast’s Ryoncil for SR-aGvHD treatment
Mesoblast has gained US FDA approval for its mesenchymal stromal cell (MSC) therapy, Ryoncil (remestemcel-L), to treat SR-aGvHD.
Mesoblast has received FDA approval for its drug Ryoncil
Mesoblast shareholders are sitting on as much as 10-fold gains for the year, after the US Food and Drug Administration ...